Literature DB >> 11686353

Structure and biology of tissue factor pathway inhibitor.

M S Bajaj1, J J Birktoft, S A Steer, S P Bajaj.   

Abstract

Human tissue factor pathway inhibitor (TFPI) is a modular protein comprised of three Kunitz type domains flanked by peptide segments that are less structured. The sequential order of the elements are: an N-terminal acidic region followed by the first Kunitz domain (K1), a linker region, a second Kunitz domain (K2), a second linker region, the third Kunitz domain (K3), and the C-terminal basic region. The K1 domain inhibits factor VIIa complexed to tissue factor (TF) while the K2 domain inhibits factor Xa. No direct protease inhibiting functions have been demonstrated for the K3 domain. Importantly, the Xa-TFPI complex is a much more potent inhibitor of the VIIa-TF than TFPI by itself. Furthermore, the C-terminal basic region of TFPI is required for rapid physiologic inhibition of coagulation and is needed for the inhibition of smooth muscle cell proliferation. Although a number of additional targets for attachment have been reported, the C-terminal basic region appears to play an important role in binding of TFPI to cell surfaces. A primary site of TFPI synthesis is endothelium and the endothelium-bound TFPI contributes to the antithrombotic potential of the vascular endothelium. Further, increased levels of plasma TFPI under septic conditions may represent endothelial dysfunction. We have proposed that the extravascular cells that synthesize TF also synthesize TFPI providing dual components necessary for the regulation of clotting in their microenvironment. Like the TF synthesis in these cells is augmented by serum, so is the case with the TFPI gene expression. TFPI gene knock out mice reveal embryonic lethality suggesting a possible role of this protein in early development. Since TF-induced coagulation is thought to play a significant role in many disease states, including disseminated intravascular clotting, sepsis, acute lung injury and cancer, recombinant TFPI may be a beneficial therapeutic agent in these disease states to attenuate pathologic clotting. The purpose of this review is to outline recent developments in the field related to the structural specificity and biology of TFPI.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11686353

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  46 in total

1.  Factor Xa-A pleuripotential protease.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2003-02       Impact factor: 2.300

Review 2.  Choice of agents to limit the coagulation cascade in acute coronary syndromes.

Authors:  Richard C Becker
Journal:  Curr Cardiol Rep       Date:  2002-07       Impact factor: 2.931

3.  Expression and characterization of wild-type TFPI and the [P151L]TFPI mutant in insect cells.

Authors:  Elmar Thyzel; Sabine Siegling; Thomas Brinkmann; Knut Kleesiek; Christian Götting
Journal:  Mol Cell Biochem       Date:  2006-02       Impact factor: 3.396

4.  Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor.

Authors:  Richard C Becker; John H Alexander; Youfu Li; Thomas Robertson; Satoshi Kunitada; Frederick A Spencer; Hongqiu Yang; Robert A Harrington
Journal:  J Thromb Thrombolysis       Date:  2004-12       Impact factor: 2.300

5.  p21-activated kinase-1 signaling regulates transcription of tissue factor and tissue factor pathway inhibitor.

Authors:  Beatriz Sánchez-Solana; Mona Motwani; Da-Qiang Li; Jeyanthy Eswaran; Rakesh Kumar
Journal:  J Biol Chem       Date:  2012-10-04       Impact factor: 5.157

6.  Glypican-3-mediated inhibition of CD26 by TFPI: a novel mechanism in hematopoietic stem cell homing and maintenance.

Authors:  Satish Khurana; Lia Margamuljana; Chacko Joseph; Sarah Schouteden; Shannon M Buckley; Catherine M Verfaillie
Journal:  Blood       Date:  2013-01-17       Impact factor: 22.113

Review 7.  Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets.

Authors:  Shiro Koizume; Yohei Miyagi
Journal:  World J Clin Oncol       Date:  2014-12-10

8.  Tissue Factor Facilitates Wound Healing in Human Airway Epithelial Cells.

Authors:  Michael D Davis; Isao Suzaki; Shuichi Kawano; Kosaku Komiya; Qing Cai; Youngman Oh; Bruce K Rubin
Journal:  Chest       Date:  2018-10-22       Impact factor: 9.410

9.  Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes.

Authors:  Trine B Opstad; Alf Age Pettersen; Thomas Weiss; Harald Arnesen; Ingebjørg Seljeflot
Journal:  Thromb J       Date:  2010-05-05

10.  Novel venom gene discovery in the platypus.

Authors:  Camilla M Whittington; Anthony T Papenfuss; Devin P Locke; Elaine R Mardis; Richard K Wilson; Sahar Abubucker; Makedonka Mitreva; Emily S W Wong; Arthur L Hsu; Philip W Kuchel; Katherine Belov; Wesley C Warren
Journal:  Genome Biol       Date:  2010-09-29       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.